Faeth Therapeutics (FTH) Total Current Liabilities (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Total Current Liabilities came in at $14.2 million in Q1 2026, up 171.37% YoY from $5.2 million in Q1 2025, and up 233.8% on a QoQ basis from $4.3 million in Q4 2025.
Faeth Therapeutics (FTH) Total Current Liabilities (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Total Current Liabilities data on file, last reported at $14.2 million in Q1 2026.
- Quarterly Total Current Liabilities rose 171.37% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (up 171.37% YoY) and the FY2025 annual result came in at $4.3 million, down 21.97% from the prior year.
- Total Current Liabilities rose to $14.2 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $14.2 million in Q1 2026 to a low of $3.9 million in Q2 2025.
- A 5-year average of $6.4 million and a median of $5.4 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 22948.48% — and 2023, when it sank 37.76%.
- Tracing FTH's Total Current Liabilities over 5 years: stood at $9.1 million in 2022, then slumped by 37.76% to $5.6 million in 2023, then declined by 3.46% to $5.4 million in 2024, then retreated by 21.97% to $4.3 million in 2025, then jumped by 233.8% to $14.2 million in 2026.
- The last three Total Current Liabilities figures came in at $14.2 million (Q1 2026), $4.3 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 630.93 Mn |
| 10 | Faeth Therapeutics | 179.40 Mn | 179.40 Mn | - | 9.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.58 Mn |
| Mar 31, 2026 | 14.19 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Sep 30, 2025 | 4.44 Mn |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Sep 30, 2024 | 5.44 Mn |
| Jun 30, 2024 | 4.95 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Dec 31, 2023 | 5.64 Mn |
| Sep 30, 2023 | 6.23 Mn |
| Jun 30, 2023 | 5.36 Mn |
| Mar 31, 2023 | 7.58 Mn |
| Dec 31, 2022 | 9.07 Mn |
| Sep 30, 2022 | 8.49 Mn |
| Jun 30, 2022 | 5.43 Mn |
| Mar 31, 2022 | 7.61 Mn |
| Dec 31, 2021 | 4.89 Mn |
| Sep 30, 2021 | 5.26 Mn |